Devonian Health Group Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DVHGF research report →
Price Chart
About the company
Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis.
- CEO
- Andre Boulet
- IPO
- 2022
- Employees
- 8
- HQ
- Québec, QC, CA
Get TickerSpark's AI analysis on DVHGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.47M
- P/E
- -4.40
- PEG
- 0.09
- P/S
- 10.15
- P/B
- 3.82
- EV/EBITDA
- -2.40
- Div Yield
- 0.00%
- Gross Margin
- 58.11%
- Op Margin
- -230.37%
- Net Margin
- -227.68%
- ROE
- -77.36%
- ROIC
- -84.35%
Latest fiscal year · YoY change
- Revenue
- $17.03M-4.4%
- Gross Profit
- $8.56M+42.9%
- Op Income
- $-1,027,425
- Net Income
- $-4,339,852-254.4%
- EPS
- $-1.76-253.0%
- OCF Growth
- -116.0%
- FCF Growth
- -116.2%
- 52W High
- $10.80
- 52W Low
- $4.27
- 50D MA
- $7.58
- 200D MA
- $7.55
- Beta
- 1.26
- RSI (14)
- 49
- Avg Volume
- 1
No earnings-call transcripts are available for DVHGF yet.
- Free Float
- 87.9%
- Shares Outstanding
- 2.78M
- Float Shares
- 2.44M
Our DVHGF coverage
Recent articles, reports, and earnings notes.
No research on DVHGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DVHGF report →Devonian Health Group Anticipates to Commence Trading on the NYSE American
prnewswire.com · Aug 18
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
gurufocus.com · Jul 27
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
prnewswire.com · Jul 27
Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
prnewswire.com · Jul 21
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
gurufocus.com · Jun 29
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
prnewswire.com · Jun 29
Devonian Reports Results of its Annual General and Special Meeting of Shareholders
prnewswire.com · Mar 30
Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
prnewswire.com · Mar 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.